Efficacy and safety of donepezil in patients with alzheimers disease in assisted living facilities

American Journal of Alzheimer's Disease and other Dementias

Volumn 25, Issue 6, 2010, Pages 483-489

  Rosenblatt, Adam ^a   Gao, Jeff ^b   MacKell, Joan ^c   Richardson, Sharon ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EISAI INC   (United States)

^c PFIZER INC   (United States)

Author keywords

Alzheimers disease; assisted living facilities; dementia screening; donepezil

Indexed keywords

DONEPEZIL;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; ASSISTED LIVING FACILITY; BACKACHE; COGNITION; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; FALLING; FEMALE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NAUSEA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; URINARY TRACT INFECTION; URINE INCONTINENCE; VOMITING; WEIGHT REDUCTION;

EID: 77956492459     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317510372923     Document Type: Article

References (32)

1. Wright B. Assisted living in the United States. AARP Public Policy Institute. http://assets.aarp.org/rgcenter/post.import/fs62-assisted.pdf. Accessed April 7, 2009.
2. Mollica R. State assisted living policy 2002. AARP Public Policy Institute. http://www.nashp.org/Files/ltc-15-AL-2002.pdf. Accessed April 7, 2009.
3. National Center for Assisted Living. Resident profile. National Center for Assisted Living Web site. www.ahcancal.org/ncal/resources/Pages/ ResidentProfile.aspx. Accessed November 18, 2009.
4. Rosenblatt A., Samus QM, Steele CD, et al. The Maryland Assisted Living Study: prevalence, recognition, and treatment of dementia and other psychiatric disorders in the assisted living population of central Maryland. J Am Geriatr Soc. 2004 ; 52 (10). 1618-1625.
5. Magsi H., Malloy T. Underrecognition of cognitive impairment in assisted living facilities. J Am Geriatr Soc. 2005 ; 53 (2). 295-298.
6. Carlson JM, Gerding G., Estoup MW Evaluation of demographics and medication use in patients with dementia in assisted living and skilled nursing facilities. Consult Pharm. 2005 ; 20 (7). 584-594.
7. Geldmacher DS, Frolich L., Doody RS, et al. Realistic expectations for treatment success in Alzheimers disease. J Nutr Health Aging. 2006 ; 10 (5). 417-429.
8. Beusterien KM, Thomas SK, Gause D., Kimel M., Arcona S., Mirski D. Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs. 2004 ; 18 (15). 1143-1148.
9. Geldmacher DS, Provenzano G., McRae T., Mastey V., Ieni JR Donepezil is associated with delayed nursing home placement in patients with Alzheimers disease. J Am Geriatr Soc. 2003 ; 51 (7). 937-944.
10. Gillette-Guyonnet S., Andrieu S., Cortes F., et al. Outcome of Alzheimers disease: potential impact of cholinesterase inhibitors. J Gerontol A Biol Sci Med Sci. 2006 ; 61 (5). 516-520.
11. Lopez OL, Becker JT, Wisniewski S., Saxton J., Kaufer DI, DeKosky ST Cholinesterase inhibitor treatment alters the natural history of Alzheimers disease. J Neurol Neurosurg Psychiatry. 2002 ; 72 (3). 310-314.
12. Lopez OL, Becker JT, Saxton J., Sweet RA, Klunk W., DeKosky ST Alteration of a clinically meaningful outcome in the natural history of Alzheimers disease by cholinesterase inhibition. J Am Geriatr Soc. 2005 ; 53 (1). 83-87.
13. Feldman H., Gauthier S., Hecker J., et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimers disease and the effect on caregiver burden. J Am Geriatr Soc. 2003 ; 51 (6). 737-744.
14. Winblad B., Kilander L., Eriksson S., et al. Donepezil in patients with severe Alzheimers disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006 ; 367 (9516). 1057-1065.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition-Text Revision. Washington, DC: American Psychiatric Association Press ; 2000.
16. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EM Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology. 1984 ; 34 (7). 939-944.
17. Folstein MF, Folstein SE, McHugh PR "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 ; 12 (3). 189-198.
18. Cummings JL, Mega M., Gray K., Rosenberg-Thompson S., Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 ; 44 (12). 2308-2314.
19. McCarron M., Gill M., Lawlor B., Beagly C. A pilot study of the reliability and validity of the Caregiver Activity Survey-Intellectual Disability (CAS-ID). J Intellect Disabil Res. 2002 ; 46 (pt 8). 605-612.
20. Rabins PV, Kasper JD, Kleiman L., Black BS, Patrick DL Concepts and methods in the development of the ADRQL: an instrument for assessing health-related quality of life in persons with Alzheimers disease. J Mental Health Aging. 1999 ; 5: 33-48.
21. Gelinas I., Gauthier L., McIntyre M., Gauthier S. Development of a functional measure for persons with Alzheimers disease: the disability assessment for dementia. Am J Occup Ther. 1999 ; 53 (5). 471-481.
22. Whitehead A., Perdomo C., Pratt RD, Birks J., Wilcock GK, Evans JG Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimers disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry. 2004 ; 19 (7). 624-633.
23. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology. 2001 ; 57 (3). 481-488.
24. Rogers SL, Friedhoff LT and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimers disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996 ; 7 (6). 293-303.
25. Rogers SL, Doody RS, Mohs RC, Friedhoff LT the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998 ; 158 (9). 1021-1031.
26. Rogers SL, Farlow MR, Doody RS, Mohs R., Friedhoff LT Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimers disease. Neurology. 1998 ; 50 (1). 136-145.
27. Seltzer B., Zolnouni P., Nunez M., et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol. 2004 ; 61 (12). 1852-1856.
28. Winblad B., Engedal K., Soininen H., et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001 ; 57 (3). 489-495.
29. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimers disease in the nursing home setting. J Am Geriatr Soc. 2001 ; 49 (12). 1590-1599.
30. Feldman H., Gauthier S., Hecker J., Vellas B., Subbiah P., Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimers disease. Neurology. 2001 ; 57 (4). 613-620.
31. Burns A., Rossor M., Hecker J., et al. The effects of donepezil in Alzheimers disease: results from a multinational trial. Dement Geriatr Cogn Disord. 1999 ; 10 (3). 237-244.
32. Winblad B., Black SE, Homma A., et al. Donepezil treatment in severe Alzheimers disease: a pooled analysis of three clinical trials. Curr Med Res Opin. 2009 ; 25 (11). 2577-2587.